StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Kavita Jain, Arihant Capital Markets

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byKavita Jain, Arihant Capital MarketsHorizon: NA (inferred Swing (≤2wk))6 Oct 2026via CNBC Awaaz.

Entry₹1,162.5Inferred
Target₹1,175
Total upside +1.08%
Stop loss₹1,145-1.51% risk
CMP₹1,159.51h ago
Active-0.26%+1.34%upside left 13d left
Follow Kavita Jain for new calls(46% target hit, 61 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 3 other Swing calls on ZYDUSLIFESee 162 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 6 Oct, 5:26 pm IST
6 supporting2 neutral1 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·6 Oct · today

Zydus Lifesciences and MSN have partnered to launch the first generic version of Adempas (Riociguat tablets) in the U.S. market.

BSE · Company Update·5 Oct · today

(opens in new tab)

The USFDA concluded a cGMP inspection at the company's SEZ II manufacturing plant in Ahmedabad with only one observation and no data integrity issues.

BSE · Company Update·28 Sept · 1w ago

(opens in new tab)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·29 Sept · 1w ago

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (2)

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 1w ago

(opens in new tab)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

Past week's volume 1.6× the 30-day average

Technicals · volume·5 Oct · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Kavita Jain, Arihant Capital Markets

Every call and its outcome